Your browser doesn't support javascript.
loading
Risk of malignancy in small pancreatic cysts decreases over time.
Ciprani, D; Weniger, M; Qadan, M; Hank, T; Horick, N K; Harrison, J M; Marchegiani, G; Andrianello, S; Pandharipande, P V; Ferrone, C R; Lillemoe, K D; Warshaw, A L; Bassi, C; Salvia, R; Fernández-Del Castillo, C.
Afiliação
  • Ciprani D; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.
  • Weniger M; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Qadan M; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Hank T; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Horick NK; Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Harrison JM; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Marchegiani G; Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.
  • Andrianello S; Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.
  • Pandharipande PV; Department of Radiology, Institute for Technology Assessment, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Ferrone CR; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Lillemoe KD; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Warshaw AL; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Bassi C; Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.
  • Salvia R; Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.
  • Fernández-Del Castillo C; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: CFernandez@mgh.harvard.edu.
Pancreatology ; 20(6): 1213-1217, 2020 Sep.
Article em En | MEDLINE | ID: mdl-32819844
BACKGROUND: Pancreatic cysts <15 mm without worrisome features have practically no risk of malignancy at the time of diagnosis but this can change over time. Optimal duration of follow-up is a matter of debate. We evaluated predictors of malignancy and attempted to identify a time to safely discontinue surveillance. METHODS: Bi-centric study utilizing prospectively collected databases of patients with pancreatic cysts measuring <15 mm and without worrisome features who underwent surveillance at the Massachusetts General Hospital (1988-2017) and at the University of Verona Hospital Trust (2000-2016). The risk of malignant transformation was assessed using the Kaplan-Meier method and parametric survival models, and predictors of malignancy were evaluated using Cox regression. RESULTS: 806 patients were identified. Median follow-up was 58 months (6-347). Over time, 58 (7.2%) cysts were resected and of those, 11 had high grade dysplasia (HGD) or invasive cancer. Three additional patients had unresectable cancer for a total rate of malignancy of 1.7%. Predictors of development of malignancy included an increase in size ≥2.5 mm/year (HR = 29.54, 95% CI: 9.39-92.91, P < 0.001) and the development of worrisome features (HR = 9.17, 95% CI: 2.99-28.10, P = 0.001). Comparison of parametric survival models suggested that the risk of malignancy decreased after three years of surveillance and was lower than 0.2% after five years. CONCLUSIONS: Pancreatic cysts <15  mm at the time of diagnosis have a very low risk of malignant transformation. Our findings indicate the risk decreases over time. Size increase of ≥2.5 mm/year is the strongest predictor of malignancy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cisto Pancreático / Neoplasias Pancreáticas / Transformação Celular Neoplásica Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Pancreatology Assunto da revista: ENDOCRINOLOGIA / GASTROENTEROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cisto Pancreático / Neoplasias Pancreáticas / Transformação Celular Neoplásica Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Pancreatology Assunto da revista: ENDOCRINOLOGIA / GASTROENTEROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália País de publicação: Suíça